Corvus Pharmaceuticals Inc (CRVS)
2.16
+0.05
(+2.37%)
USD |
NASDAQ |
May 31, 16:00
2.15
-0.01
(-0.46%)
After-Hours: 20:00
Corvus Pharmaceuticals Research and Development Expense (Annual): 16.53M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.53M |
| December 31, 2022 | 24.47M |
| December 31, 2021 | 29.12M |
| December 31, 2020 | 31.83M |
| December 31, 2019 | 37.98M |
| Date | Value |
|---|---|
| December 31, 2018 | 38.59M |
| December 31, 2017 | 46.30M |
| December 31, 2016 | 29.36M |
| December 31, 2015 | 11.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.53M
Minimum
2023
37.98M
Maximum
2019
27.98M
Average
29.12M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Cyclacel Pharmaceuticals Inc | 19.16M |
| Enanta Pharmaceuticals Inc | 163.52M |
| Oragenics Inc | 15.49M |
| Nanoviricides Inc | 6.392M |
| MAIA Biotechnology Inc | 11.11M |